Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009522.pdf
0001179110-17-009522.rtf
0001179110-17-009522.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009521.pdf
0001179110-17-009521.rtf
0001179110-17-009521.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009523.pdf
0001179110-17-009523.rtf
0001179110-17-009523.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009520.pdf
0001179110-17-009520.rtf
0001179110-17-009520.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-17-004926.pdf
0001558370-17-004926.rtf
0001558370-17-004926.xls
DEFA14A

Additional proxy soliciting materials - definitive

 View HTML
0001558370-17-004788.pdf
0001558370-17-004788.rtf
0001558370-17-004788.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-17-004674.pdf
0001558370-17-004674.rtf
0001558370-17-004674.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-17-003322.pdf
0001558370-17-003322.rtf
0001558370-17-003322.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-17-003397.pdf
0001558370-17-003397.rtf
0001558370-17-003397.xls
EX-101.INS - EX-101.INS
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000921895-17-001268.pdf
0000921895-17-001268.rtf
0000921895-17-001268.xls